Comments on: Biotech Portfolio Updates- Buying More Immunogen

By: Ohad Hammer

Ohad Hammer — Wed, 12 Nov 2008 05:35:24 +0000

Estimated to be ~7%

By: bassel

bassel — Tue, 11 Nov 2008 22:44:35 +0000

Good info. Can you tell us the royalty rate on t-dm1 both in the u.s. and internationaly

By: Ohad Hammer

Ohad Hammer — Mon, 03 Nov 2008 21:49:17 +0000

Sorry, I don’t follow them.

ohad

By: dean

dean — Sun, 02 Nov 2008 23:04:17 +0000

Any thoughts re Neurogesx and their recent FDA filing for their pain patch in postherpetic neuralgia?

By: Ohad Hammer

Ohad Hammer — Sat, 01 Nov 2008 09:24:41 +0000

Thanks ihope2,

That’s a very tough question that in most cases shouldn’t be a factor in biotech companies like IMGN. I have no idea what will happen with the stock, but as you are well aware, it is a highly volatile stock, so it all depends on your risk tolerance and for what % of your portfolio IMGN accounts.

In terms of meaningful data, Nothing is due till december, when data for T-DM1 and IMGN901 will be released. I expect the prior to be pretty good and the latter to be ok but not explosive.
Unfotunately, data for SAR3419 ( the Sanofi CD19 ADC) will be presented only next year, and the AVE9633 was discotinued, so no new data from Sanofi this year, but potential INDs for SAR566658 and SAR650984.

hope this helps,
Ohad

By: ihope2

ihope2 — Fri, 31 Oct 2008 17:05:47 +0000

Great call on IMGN.

i added a nice chunk at 3.6 $ after your article, and am now up 25% in just 2 weeks. Where do you see the stock going in the coming month or two?
I plan to hold a my core position anyway, I am just referring to the extra stocks I have.
thank you!

By: Eugene

Eugene — Wed, 22 Oct 2008 09:40:12 +0000

Now everyone is talking about the American economy and eclections, nice to read something different. Eugene

By: Hillary Martin

Hillary Martin — Mon, 20 Oct 2008 10:00:52 +0000

Nice blog, I love to see this kind of content, keep up the good work.

By: Ohad Hammer

Ohad Hammer — Thu, 16 Oct 2008 21:22:33 +0000

druggie
I agree that most people who were familiar with the story expected this, but Genentech’s formal announcement combined with a nice milestone payment should have an impact imo.

I don’t know if the data at SABC will “blow away scientists and investors”, but I am hearing good things about the data.

ohad

By: druggie

druggie — Thu, 16 Oct 2008 13:43:19 +0000

ohad.. dna moving forward was a poorly kept secret.. announcements by dna that either of the two current phase 2 trials could be registrational was the first tip-off to investors and wall street, and that was announced in the spring of 2008.

Wall street is way behind the curve on IMGN.. you are correct. We also know that tras-dm1 works very well, and while the actual data has not been released in this subset of patients.. dna did announce that 42% of the patients studied in the first phase 2 trial had already failed a tykerb/xeloda regimen. Giving credence to dna moving forward very quickly against that patient population with both a pivotal phase 2 and pivotal phase 3 trial for 3rd and 2nd line therapy. I would expect the data that DNA presents at the SABC in december 2008, though incomplete will blow away scientists and investors and the stimulant to drive the stock price back to the 5-7 range.. or a 50-100 % return over the next 3-6 months.

druggie